2,290
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Boehringer Ingelheim's recently active trials. Comparator arms are excluded.
- Ezabenlimab7 trials
- Nerandomilast6 trials
- BI 7645325 trials
- Zongertinib5 trials
- Carboplatin4 trials
- Empagliflozin4 trials
Upcoming readouts
Next primary completion dates among Boehringer Ingelheim's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- Mar 2027A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic P…Phase 2
- Apr 2027A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With…Phase 3
- Apr 2027FIBRONEER™-ON: A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibros…Phase 3
- Jun 2027The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With BronchiectasisPhase 3
- Jul 2027A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic Diseas…Phase 3
- Jul 2027A Study to Test Whether BI 3032950 Helps People With Ulcerative ColitisPhase 2
Top therapeutic areas
Conditions studied most often across Boehringer Ingelheim's recently active trials.
- Obesity7 trials
- Small Cell Lung Carcinoma (SCLC)4 trials
- Heart Failure4 trials
- Solid Tumours4 trials
- Idiopathic Pulmonary Fibrosis4 trials
- Chronic Kidney Disease3 trials
Boehringer Ingelheim pipeline by phase
The main study drugs across 86 active trials Boehringer Ingelheim leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 39 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| ObrixtamigBI 764532 | 11 | 5 | Sept 2026 est. | NCT07544654 · NCT07472517 · NCT05882058 |
| Nerandomilast | 7 | 5 | Apr 2027 est. | NCT07789015 · NCT07540988 · NCT07497087 |
| zongertinib | 6 | 4 | Dec 2026 est. | NCT07195695 · NCT06151574 · NCT07486817 |
| SurvodutideBI 456906 | 5 | 3 | Jan 2027 est. | NCT07754461 · NCT06632457 · NCT06632444 |
| VerducatibBI 1291583 | 5 | 3 | Dec 2026 est. | NCT06872892 · NCT05846230 · NCT07781631 |
| vicadrostatBI 690517 | 4 | 4 | May 2028 est. | NCT07064473 · NCT06935370 · NCT06531824 |
| Empagliflozin | 3 | 1 | Mar 2027 est. | NCT07107945 · NCT07044700 · NCT06527846 |
| BI 764198 | 2 | 2 | Jan 2028 est. | NCT07220083 · NCT07355296 |
| Tenecteplase | 1 | 1 | Oct 2027 est. | NCT07361302 |
Phase 210 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| BI 3000202 | 3 | 3 | Oct 2026 est. | NCT07409181 · NCT07774325 · NCT07486102 |
| BI 3034701 | 3 | 1 | Dec 2026 est. | NCT07662122 · NCT07754474 · NCT07693231 |
| BI 1584862 | 1 | — | Dec 2026 est. | NCT06769048 |
| BI 1815368 | 1 | 1 | Sept 2027 est. | NCT06962839 |
| BI 3032950 intravenous (Part A) | 1 | 1 | Jul 2027 est. | NCT06636656 |
| BI 3802876 | 1 | 1 | Aug 2027 est. | NCT07325526 |
| BI 764524 | 1 | — | Mar 2027 est. | NCT06321302 |
| BI 765423 | 1 | 1 | Mar 2027 est. | NCT07036523 |
| BI 771716 | 1 | — | Oct 2026 est. | NCT06722157 |
| Brigimadlin | 1 | — | Dec 2030 est. | NCT06619509 |
Phase 124 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| BI 770371 | 2 | — | Aug 2027 est. | NCT06806852 · NCT05327946 |
| BI 1701963 | 1 | — | Mar 2028 est. | NCT04111458 |
| BI 1703880 | 1 | 1 | Sept 2028 est. | NCT05471856 |
| BI 1823911 | 1 | — | Nov 2026 est. | NCT04973163 |
| BI 3000202_low dose | 1 | — | Dec 2026 est. | NCT06878365 |
| BI 3034701 (C-14) | 1 | 1 | Oct 2026 est. | NCT07708493 |
| BI 3720931 | 1 | — | Oct 2040 est. | NCT06962852 |
| BI 3776528 | 1 | 1 | Feb 2027 est. | NCT06745297 |
| BI 3804379 | 1 | 1 | Feb 2028 est. | NCT06575400 |
| BI 3810944 | 1 | 1 | Oct 2029 est. | NCT07224425 |
| BI 3814916 | 1 | 1 | Jul 2027 est. | NCT07486115 |
| BI 3819026 | 1 | 1 | Jun 2028 est. | NCT07607678 |
| BI 3820768 | 1 | 1 | Sept 2029 est. | NCT07306559 |
| BI 3821001 | 1 | — | Oct 2026 est. | NCT07526194 |
| BI 3822971 | 1 | — | Jan 2030 est. | NCT07744152 |
| BI 765049 | 1 | — | — | NCT06882746 |
| BI 765063 | 1 | — | — | NCT05068102 |
| BI 765179 | 1 | — | — | NCT04958239 |
| Formulation A | 1 | — | Jan 2027 est. | NCT07407348 |
| Low dose BI 3812465 | 1 | 1 | Mar 2027 est. | NCT07553429 |
| Sifrol® | 1 | — | — | NCT07727785 |
| Survodutide formulation B2 | 1 | 1 | Dec 2026 est. | NCT07768813 |
| VSV-GP154 | 1 | — | Mar 2027 est. | NCT05846516 |
| Zongertinib, Formulation A, reference product | 1 | 1 | Dec 2026 est. | NCT07789028 |
Derived from 86 active trials Boehringer Ingelheim leads; 84 name an intervention, folding into 43 phased drugs. 1 intervention carries no registry phase (observational studies, tests and devices) and is not shown. This is ComplyRx's reading of the registry, not Boehringer Ingelheim's own pipeline disclosure.
Boehringer Ingelheim trials
The 50 most significant of Boehringer Ingelheim's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| A Study to Test How BI 764532 is Taken up by Tumours in People With Small-cell Lung Cancer or Neuroendocrine CancerNCT05963867BI 764532 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 12 est. | 30 Sept 2026 |
| Emotional and Social Experiences of Antifibrotic (AF) Therapy Among Idiopathic Pulmonary Fibrosis (IPF)/Progressive Pulmonary Fibrosis (PPF) Patients: A Real-World StudyNCT07743996 | — | Not yet scored | OngoingRecruiting | 100 est. | 30 Sept 2026 |
| A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are ToleratedNCT07526194BI 3821001 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 72 est. | 2 Oct 2026 |
| A Study in Healthy Men to Find Out How Blocking Certain Transport Proteins Affects the Amount of BI 3000202 in the BloodNCT07774325BI 3000202 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 16 est. | 6 Oct 2026 |
| A Study to Test How Well Different Doses of BI 3031185 Are Tolerated by Healthy Men and WomenNCT06916702BI 3031185 | Phase 1 | Locked · track to reveal | OngoingSuspended | 100 est. | 7 Oct 2026 |
| A Study to Test How BI 3034701 is Taken up and Processed by the Body in Healthy Men With Normal Weight or OverweightNCT07708493BI 3034701 (C-14) | Phase 1 | Locked · track to reveal | OngoingRecruiting | 8 est. | 14 Oct 2026 |
| A Study in Japanese Healthy Men to Test How Well Different Doses of BI 3031185 Are Tolerated and a Study in Japanese Healthy Women to Test Whether BI 3031185 Influences the Amount of a Contraceptive in the BloodNCT07656792BI 3031185 | Phase 1 | Not yet scored | OngoingSuspended | 36 est. | 26 Nov 2026 |
| A Study to Test How Well BI 3000202 is Tolerated by People With Type 1 InterferonopathiesNCT06878365BI 3000202_low dose | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 16 est. | 6 Dec 2026 |
| A Study to Compare How 2 Different Formulations of Survodutide Are Taken up in the Body When Given by Injection in Healthy Men and Women With and Without Overweight or ObesityNCT07768813Survodutide formulation A | Phase 1 | Locked · track to reveal | OngoingRecruiting | 44 est. | 8 Dec 2026 |
| A Study in Healthy Men to Test Whether Carbamazepine Influences the Amount of Verducatib in the BloodNCT07781631Verducatib | Phase 1 | Not yet scored | OngoingNot yet recruiting | 20 est. | 14 Dec 2026 |
| A Study in Healthy People to Test How Zongertinib is Taken up in the Body When Given as Tablets Made by Two Different Manufacturers With or Without FoodNCT07789028Zongertinib, Formulation A, reference product | Phase 1 | Locked · track to reveal | OngoingRecruiting | 56 est. | 15 Dec 2026 |
| A Study in Healthy People to Measure How Different Doses of Verducatib Affect the HeartNCT07760246Verducatib | Phase 1 | Locked · track to reveal | OngoingRecruiting | 56 est. | 16 Dec 2026 |
| A Study to Test How BI 1291583 is Taken up in the Blood of People With and Without Liver ProblemsNCT07023354BI 1291583 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 32 est. | 23 Dec 2026 |
| SGLT2 Inhibitors and Renal Anemia in Japan: RWDNCT07063316SGLT2 inhibitor | — | Not yet scored | OngoingActive, not recruiting | 15,000 est. | 25 Dec 2026 |
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)NCT04886804zongertinib | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 554 est. | 30 Dec 2026 |
| A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the LiverNCT05202353BI 456906 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 29 est. | 6 Jan 2027 |
| A Study in People With Overweight or Obesity to Compare How 2 Different Formulations of Survodutide Are Taken up by the BodyNCT07407348Formulation A | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 80 est. | 26 Jan 2027 |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic RetinopathyNCT06321302BI 764524 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 190 est. | 5 Mar 2027 |
| A Study to Evaluate ATP150/ATP152/ATP162, VSV-GP154 and Ezabenlimab in Patients With Pancreatic Ductal AdenocarcinomaNCT05846516VSV-GP154 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 59 est. | 8 Mar 2027 |
| A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard TreatmentNCT07036523BI 765423 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 71 est. | 11 Mar 2027 |
| A Study in People With Diabetic Macular Edema to Test How Well Different Doses of BI 3812465 Are ToleratedNCT07553429Low dose BI 3812465 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 49 est. | 23 Mar 2027 |
| DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent ChemotherapyNCT05990738BI 764532 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 69 est. | 30 Mar 2027 |
| Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This MedicineNCT05846230BI 1291583 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 268 est. | 31 Mar 2027 |
| DAREONᵀᴹ-8DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung CancerNCT06077500BI 764532 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 46 est. | 31 Mar 2027 |
| A Study to Find Out How EMPAgliflozin is Tolerated and if it Helps Children and Adolescents With Chronic KIDNEY Disease (EMPA-KIDNEY® Kids)NCT07107945Empagliflozin | Phase 3 | Locked · track to reveal | OngoingRecruiting | 120 est. | 16 Apr 2027 |
| FIBRONEER™-ONA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With NerandomilastNCT06238622Nerandomilast | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,700 est. | 28 Apr 2027 |
| The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With BronchiectasisNCT06872892BI 1291583 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,755 est. | 15 Jun 2027 |
| A Study to Test How Well Different and Multiple Doses of BI 3034701 Are Tolerated in People Living With Overweight or ObesityNCT07754474BI 3034701 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 70 est. | 21 Jun 2027 |
| A Study to Test Whether Nerandomilast Helps People With Lungfibrosis Related to Rheumatic DiseasesNCT06806592Nerandomilast | Phase 3 | Locked · track to reveal | OngoingRecruiting | 400 est. | 17 Jul 2027 |
| A Study to Test Whether BI 3032950 Helps People With Ulcerative ColitisNCT06636656BI 3032950 intravenous (Part A) | Phase 2 | Locked · track to reveal | OngoingRecruiting | 80 est. | 30 Jul 2027 |
| A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or OverweightNCT07662122BI 3034701 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 342 est. | 4 Aug 2027 |
| A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)NCT07325526BI 3802876 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 30 est. | 5 Aug 2027 |
| A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With a Tumour in the Brain That is Positive for DLL3NCT05916313BI 764532 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 20 est. | 9 Aug 2027 |
| Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without PembrolizumabNCT07486817Zongertinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 60 est. | 12 Aug 2027 |
| A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab AloneNCT06806852BI 770371 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 91 est. | 31 Aug 2027 |
| A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular EdemaNCT06962839BI 1815368 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 300 est. | 1 Sept 2027 |
| TENACITYA Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen WellNCT07361302Tenecteplase | Phase 3 | Locked · track to reveal | OngoingRecruiting | 1,325 est. | 2 Oct 2027 |
| DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine CancersNCT06132113BI 764532 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 65 est. | 9 Oct 2027 |
| A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)NCT05155332BI 1831169 | Phase 1 | Locked · track to reveal | OngoingSuspended | 190 est. | 13 Dec 2027 |
| A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood SugarNCT07754461Survodutide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 600 est. | 17 Jan 2028 |
| PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney DiseaseNCT07355296BI 764198 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 132 est. | 20 Jan 2028 |
| A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)NCT04111458BI 1701963 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 71 est. | 31 Mar 2028 |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureNCT06424288vicadrostat | Phase 3 | Locked · track to reveal | OngoingRecruiting | 6,000 est. | 22 May 2028 |
| A Study in People With Advanced Cancer to Test How Well Different Doses of BI 3819026 Are Tolerated When Taken Alone and Together With EzabenlimabNCT07607678BI 3819026 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 60 est. | 5 Jun 2028 |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)NCT06531824BI 690517 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 11,000 est. | 30 Aug 2028 |
| DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard ChemoimmunotherapyNCT07472517obrixtamig | Phase 3 | Locked · track to reveal | OngoingRecruiting | 670 est. | 9 Sept 2028 |
| A Study to Test How Different Doses of BI 1703880 in Combination With Ezabenlimab Are Tolerated in People With Different Types of Advanced Cancer (Solid Tumours)NCT05471856BI 1703880 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 66 est. | 13 Sept 2028 |
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 AlterationsNCT06581432Zongertinib | Phase 2 | Locked · track to reveal | OngoingRecruiting | 588 est. | 30 Nov 2028 |
| FIBRONEER-ACT: A Study to Test Whether Nerandomilast Helps People With Fibrosing Interstitial Lung Disease at Risk for Disease ProgressionNCT07540988Nerandomilast | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 466 est. | 5 Dec 2028 |
| A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)NCT07220083BI 764198 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 286 est. | 27 Dec 2028 |